BioSyent Declares Fourth Quarter 2024 Dividend

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

MISSISSAUGA, Ontario, Nov. 20, 2024 (GLOBE NEWSWIRE) — BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) is pleased to announce that its Board of Directors has declared a quarterly dividend of $0.045 per common share, payable in Canadian Dollars on December 16, 2024, to shareholders of record at the close of business on November 29, 2024. This fourth quarter 2024 dividend compares with the third quarter 2024 dividend of $0.045 per common share. This dividend qualifies as an ‘eligible dividend’ for Canadian income tax purposes. The declaration, timing, amount and payment of future dividends remain at the discretion of the Board of Directors.

About BioSyent Inc.

Listed on the TSX Venture Exchange under the trading symbol “RX”, BioSyent is a profitable growth-oriented specialty pharmaceutical company focused on in-licensing or acquiring innovative pharmaceutical and other healthcare products that have been successfully developed, are safe and effective, and have a proven track record of improving the lives of patients. BioSyent supports the healthcare professionals that treat these patients by marketing its products through its community, specialty and international business units.

As of the date of this press release, the Company has 11,594,101 common shares outstanding.

For a direct market quote for the TSX Venture Exchange and other Company financial information please visit www.tmxmoney.com.

For further information please contact:
Mr. René C. Goehrum
President and CEO
BioSyent Inc.
E-Mail: investors@biosyent.com
Phone: 905-206-0013
Web: www.biosyent.com

This press release may contain information or statements that are forward-looking. The contents herein represent our judgment, as at the release date, and are subject to risks and uncertainties that may cause actual results or outcomes to be materially different from the forward-looking information or statements. Potential risks may include, but are not limited to, those associated with clinical trials, product development, future revenue, operations, profitability and obtaining regulatory approvals.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.

Staff

Recent Posts

eHealth, Inc. to Hold Fourth Quarter and Fiscal Year 2024 Earnings Call on February 26 at 8:30 a.m. Eastern Time

AUSTIN, Texas, Feb. 12, 2025 /PRNewswire/ -- eHealth, Inc. (Nasdaq: EHTH), a leading private online…

4 hours ago

GRAIL to Announce Fourth Quarter 2024 Financial Results

MENLO PARK, Calif., Feb. 12, 2025 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company…

4 hours ago

ASI Reports Record $26.6 Billion in Annual Sales for Promo Products Industry

TREVOSE, Pa., Feb. 12, 2025 /PRNewswire/ -- The promotional products industry hit a record $26.6…

4 hours ago

Procurement Partners Appoints Healthcare SaaS Veteran Adam Laskey as CEO to Drive Innovation and Growth

BLOOMINGTON, Ill., Feb. 12, 2025 /PRNewswire/ -- Procurement Partners, a leading provider of spend management and…

4 hours ago

AWS Recognizes Agilisium as one of 13 Global Partners with both Generative AI and Life Sciences Consulting Competencies

LOS ANGELES, Feb. 12, 2025 /PRNewswire/ -- Agilisium, a leading data innovation partner for the…

4 hours ago